Latest News


 
    Interim data from MSKCC study  
 
    GBM Agile Update  
 
    Kazia recognises GBM Awareness Day 2022 as it expands clinical trial activity in Europe and US  
 
    Kazia launches new SAB  
 
    FDA AWARDS ORPHAN DESIGNATION TO PAXALISIB FOR ATRT  
 
    Kazia paxalisib preclinical DIPG data released at IPSNO  
 
    Kazia's Alliance study progresses to expansion phase  
 
    Kazia presents final PII data at ASCO  
 
    GBM Agile opens to paxalisib in Europe  
 
    Edison Research: Deep Dive into Childhood Brain Cancer  
 
    Kazia to present at investor conferences hosted by HC Wainwright and LD Micro  
 
    Kazia marks DIPG Awareness Day  
 
    Interview with Dr Matt Dun for World DIPG Awareness Day  
 
    Kazia to present at ASCO  
 
    Kazia presents preclinical data for paxalisib at AACR  
 
    Kazia presents on EVT801 at AACR  
 
    Kazia to present at two conferences  
 
    First patient into Cornell keto study  
 
    Quarterly Activities Report And Appendix 4c  
 
    Kazia Corporate Presentation  
 
    Kazia Therapeutics To Present At Hc Wainwright Bioconnect Conference  
 
    Kazia Therapeutics Appoints Karen Krumeich As Chief Financial Officer  
 
    Kazia Announces Positive Final Data From Phase Ii Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma  
 
    Gbm Agile Opens To Paxalisib In Canada  
 
    Kazia Therapeutics Appoints John Friend, Md, As Chief Medical Officer  
 
    Pnoc Study In Childhood Brain Cancer Enrols First Patient  
 
    Kazia Annual General Meeting Results  
 
    Kazia Annual General Meeting Results  
 
    Quarterly Activities Report And Appendix 4c  
 
    Kazia Therapeutics To Present At Hc Wainwright 23rd Annual Global Investment Conference  
 
    Evt801 Phase I Study Receives Full Regulatory Approval  
 
    Quarterly Activities Report And Appendix 4c  
 
    Kazia Calls For Increased Focus On Brain Cancer Research This Gbm Awareness Day  
 
    Kazia Provides Progress Update On Paxalisib And Evt801 Clinical Programs  
 
    Manufacturing Patents Granted For Paxalisib In Key Territories; Extend Effective Patent Protection To 2036  
 
    Kazia Enters Clinical Collaboration With Cornell University For Phase Ii Clinical Study Using Paxalisib In Combination With Ketogenic Diet For Glioblastoma  
 
    Study Of Paxalisib In Primary Cns Lymphoma At Dana-Farber Cancer Institute Enrols First Patient  
 
    Kazia Licenses Global Rights To Evt801, A Novel, First-In-Class, Clinic-Ready, Vegfr3 Inhibitor, From Evotec Se  
 
    Kazia Licenses Rights To Paxalisib In Greater China To Simcere, A Leading Chinese Pharmaceutical Company  
 
    Kazia Licenses Cantrixil, A Clinical-Stage, First-In-Class Ovarian Cancer Drug Candidate, To Oasmia Pharmacetical Ab  
 
    Gbm Agile Pivotal Study Commences Recruitment To Paxalisib Arm  
 
    Kazia Therapeutics Limited Appendix 4D Half-year report